Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience

Background and Objectives: Drug-related bradyarrhythmia is a well-documented major adverse event among beta-blocker users and a potential cause for hospitalization or additional interventions. Whether beta-blocker use is associated with specific bradyarrhythmia presentations, and how this relates to other predisposing factors, is not well known. We aim to evaluate the association between beta-blocker use and the type of atrioventricular (AV) conduction disorder in patients with symptomatic bradycardia. Materials and Methods: We conducted a retrospective cohort study on 596 patients with a primary diagnosis of symptomatic bradyarrhythmia admitted to a single tertiary referral center. Of the cases analyzed, 253 patients were on beta-blocker treatment at presentation and 343 had no bradycardic treatment. We analyzed demographics, clinical and paraclinical parameters in relation to the identified AV conduction disorder. A multivariate regression analysis was performed to explore factors associated with beta-blocker use. Results: Of the 596 patients (mean age 73.9 ± 8.8 years, 49.2% male), 261 (43.8%) had a third-degree AV block, 92 (15.4%) had a second-degree AV block, 128 (21.5%) had slow atrial fibrillation, 93 (15.6%) had sick sinus syndrome and 21 (3.5%) had sinus bradycardia/sinus pauses. Beta-blocker use was associated with the female gender (p < 0.001), emergency admission (p < 0.001), dilated cardiomyopathy (p = 0.003), the lower left ventricular ejection fraction (p = 0.02), mitral stenosis (p = 0.009), chronic kidney disease (p = 0.02), higher potassium levels (p = 0.04) and QRS duration > 120 ms (p = 0.02). Slow atrial fibrillation (OR = 4.2, p < 0.001), sick sinus syndrome (OR = 2.8, p = 0.001) and sinus bradycardia/pauses (OR = 32.9, p < 0.001) were more likely to be associated with beta-blocker use compared to the most common presentation (third-degree AV block), after adjusting for other patient characteristics. Conclusions: Beta-blocker use is more likely to be associated with slow atrial fibrillation, sick sinus syndrome and sinus bradycardia/pauses, compared to a second- or third-degree AV block, after adjusting for other patient factors such as gender, admission type, ECG, comorbidities, cardiac function and lab testing.

[1]  aguda y crónica,et al.  Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2022, Revista espanola de cardiologia.

[2]  S. Sideris,et al.  Permanent pacemaker implantation in unexplained syncope patients with electrophysiology study-proven atrioventricular node disease. , 2022, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[3]  C. Vlachopoulos,et al.  Permanent pacemaker implantation in unexplained syncope patients with borderline sinus bradycardia and electrophysiology study‐proven sinus node disease , 2020, Journal of arrhythmia.

[4]  Julie A. Johnson,et al.  Pharmacogenetic factors affecting β-blocker metabolism and response , 2020, Expert opinion on drug metabolism & toxicology.

[5]  Juan Jiménez-Jáimez,et al.  Bloqueo auriculoventricular en pacientes en tratamiento con fármacos bradicardizantes. Variables predictoras de la necesidad de implante de marcapasos , 2020 .

[6]  J. Marine,et al.  Evaluating and managing bradycardia. , 2020, Trends in cardiovascular medicine.

[7]  M. Jiménez-Navarro,et al.  Atrioventricular block in patients undergoing treatment with bradycardic drugs. Predictors of pacemaker requirement. , 2020, Revista espanola de cardiologia.

[8]  6. Glycemic Targets: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[9]  Sergio Raposeiras-Roubín,et al.  Papel de los bloqueadores beta en la enfermedad cardiovascular en 2019 , 2019, Revista Española de Cardiología.

[10]  C. Torp-Pedersen,et al.  Rate- and rhythm therapy in patients with atrial fibrillation and the risk of pacing and bradyarrhythmia. , 2019, Heart rhythm.

[11]  M. Gold,et al.  2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.

[12]  B. Ibáñez,et al.  Role of beta-blockers in cardiovascular disease in 2019. , 2019, Revista espanola de cardiologia.

[13]  M. Gold,et al.  2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay. , 2019, Circulation.

[14]  Anouk L. M. Eikendal,et al.  Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature. , 2019, JACC. Heart failure.

[15]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[16]  Deepak L. Bhatt,et al.  Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. , 2018, The American journal of medicine.

[17]  David Moher,et al.  Incidence, causes, and consequences of preventable adverse drug reactions occurring in inpatients: A systematic review of systematic reviews , 2018, PloS one.

[18]  K. Patton,et al.  Adverse drug reactions , 2018, Anaesthesia.

[19]  R. Nordin,et al.  Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. , 2017, Journal of geriatric cardiology : JGC.

[20]  K. Swedberg,et al.  Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement? , 2017, Journal of the American College of Cardiology.

[21]  J. Lekakis,et al.  Permanent pacemaker implantation in octogenarians with unexplained syncope and positive electrophysiologic testing. , 2017, Heart rhythm.

[22]  J. Lindh,et al.  Adverse Drug Reactions in a Tertiary Care Emergency Medicine Ward - Prevalence, Preventability and Reporting , 2016, PloS one.

[23]  Thomas Bürkle,et al.  Adverse drug events in patients admitted to an emergency department: an analysis of direct costs , 2015, Pharmacoepidemiology and drug safety.

[24]  S. Tobe,et al.  Contemporary use of β-blockers: clinical relevance of subclassification. , 2014, The Canadian journal of cardiology.

[25]  David G Strauss,et al.  Evaluating strict and conventional left bundle branch block criteria using electrocardiographic simulations. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  M. Sweeney Not So Temporary Pacing , 2013, Journal of cardiovascular electrophysiology.

[27]  M. Pletcher,et al.  Risk of emergent bradycardia associated with the use of carvedilol and metoprolol in routine clinical practice. , 2013, The American journal of medicine.

[28]  Lluís Mont,et al.  2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, European heart journal.

[29]  Lluís Mont,et al.  2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[30]  James L. Netterville,et al.  Clinical Practice Guideline , 2013, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[31]  A. Khwaja KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[32]  T. Chang,et al.  Chronic kidney disease and cardiovascular therapeutics: time to close the evidence gaps. , 2011, Journal of the American College of Cardiology.

[33]  W. Frishman,et al.  β‐Adrenergic Blockers , 2011, Journal of clinical hypertension.

[34]  R. Wachter,et al.  Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial , 2011, European journal of heart failure.

[35]  M. Helfand,et al.  Drug Class Review: Beta Adrenergic Blockers , 2009 .

[36]  C. Schneider,et al.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. , 2008, European heart journal.

[37]  Warren M. Smith,et al.  Metoprolol-induced hyperkalaemia in chronic respiratory acidosis. , 2007, The New Zealand medical journal.

[38]  S. Nattel,et al.  Adrenergic control of a constitutively active acetylcholine-regulated potassium current in canine atrial cardiomyocytes. , 2007, Cardiovascular research.

[39]  J. Hawboldt,et al.  Possible Metoprolol-Induced Hyperkalemia , 2006 .

[40]  K. Swedberg,et al.  Expert consensus document on beta-adrenergic receptor blockers. , 2004, European heart journal.

[41]  C. Coffey,et al.  Adverse effects of -blocker therapy for patients with heart failure: A quantitative overview of ran , 2004 .

[42]  David Zeltser,et al.  Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. , 2004, Journal of the American College of Cardiology.

[43]  S. Efrati,et al.  Adverse drug events in hospitalized patients treated with cardiovascular drugs and anticoagulants , 2002, Pharmacoepidemiology and drug safety.

[44]  M. Kapeliovich,et al.  Drug-related cardiac iatrogenic illness as the cause for admission to the intensive cardiac care unit. , 2000, The Israel Medical Association journal : IMAJ.

[45]  O. Ashouri Metoprolol-induced hyperkalemia in a diabetic with advanced renal failure. , 1985, Archives of internal medicine.

[46]  A. Levin,et al.  Practice Guideline , 2020, Encyclopedia of Behavioral Medicine.

[47]  Michael H. Olsen,et al.  ESH / ESC Guidelines for the management of arterial hypertension , 2013 .

[48]  Grupo de Trabajo,et al.  Documento de Consenso de Expertos sobre bloqueadores de los receptores β-adrenérgicos , 2005 .

[49]  M. Helfand,et al.  Drug Class Review on Beta Adrenergic Blockers , 2005 .

[50]  K. Swedberg,et al.  Expert consensus document on b-adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology Task Force Members , Jos , 2004 .

[51]  K. Swedberg,et al.  Blockers in Chronic Heart Failure , 2003 .

[52]  M. Rademaker Do Women Have More Adverse Drug Reactions? , 2001, American journal of clinical dermatology.

[53]  P. Timmermans,et al.  Differential pharmacological properties of beta-adrenoceptor blocking drugs. , 1983, Journal of cardiovascular pharmacology.

[54]  P. Timmermans,et al.  Differential Pharmacological Properties of β‐Adrenoceptor Blocking Drugs , 1983 .

[55]  Anouk L. M. Eikendal,et al.  Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women , 2022 .

[56]  Y. Yokoyama,et al.  Clinical Pharmacology: Advances and Applications Dovepress Severe Iatrogenic Bradycardia Related to the Combined Use of Beta-blocking Agents and Sodium Channel Blockers , 2022 .